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Background: In Pakistan and other countries using oral polio vaccine (OPV), immunity to type 2 poliovirus
is now maintained by a single dose of inactivated polio vaccine (IPV) in routine immunization, supple-
mented in outbreak settings by monovalent OPV type 2 (mOPV2) and IPV. While well-studied in clinical
trials, population protection against poliovirus type 2 achieved in routine and outbreak settings is gener-
ally unknown.
Methods: We conducted two phases of a population-based serological survey of 7940 children aged 6–
11 months old, between November 2016 and October 2017 from 13 polio high-risk locations in Pakistan.
Results: Type 2 seroprevalence was 50% among children born after trivalent OPV (tOPV) withdrawal
(April 2016), with heterogeneity across survey areas. Supplementary immunization activities (SIAs) with
mOPV2 followed by IPV improved population immunity, varying from 89% in Pishin to 64% in Killa
Abdullah, with little observed marginal benefit of subsequent campaigns. In the other high-risk districts
surveyed, a single SIA with IPV was conducted and appeared to improve immunity to 57% in Karachi to
84% in Khyber.
Conclusions: Our study documents declining population immunity following trivalent OPV withdrawal in
Pakistan, and wide heterogeneity in the population impact of supplementary immunization campaigns.
Differences between areas, attributable to vaccination campaign coverage, were far more important for
type 2 humoral immunity than the number of vaccination campaigns or vaccines used. This emphasizes
the importance of immunization campaign coverage for type 2 outbreak response in the final stages of
polio eradication. Given the declining type 2 immunity in new birth cohorts it is also recommended that
2 or more doses of IPV should be introduced in the routine immunization program of Pakistan.
 2020 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
1. Introduction
The use of Trivalent Oral Polio Vaccine (tOPV) has been success-
fully used to eradicate the three serotypes of polio (Type 1, 2 and 3)
globally with the exception of Pakistan, Afghanistan and Nigeria
[1,2]. The tOPV has been the vaccine of choice in polio eradication
due to its low cost and ease of use [3]. Presently wild type 1 sero-
type of polio is circulating in Pakistan where as wild type 2 has
been eradicated globally and since 2012 wild type 3 has not been
detected [2,4]. Despite its effectiveness the tOPV is genetically
unstable and has a tendency to be converted into a Sabin Like virus
and the circulating vaccine-derived polioviruses (cVDPV) conse-
quently causing the vaccine-associated paralytic poliomyelitis
(VAPP) and outbreaks of cVDPVs in areas where immunization
rates are low [3,5,6]. Among all three serotypes the type 2 compo-
nent of tOPV has caused majority of VDPV and VAPP cases [4]. As
wild type 2 poliovirus has been eradicated, the type 2 component
of OPV was withdrawn from use globally in April 2016 (OPV2 ces-
sation) to eliminate the burden of type 2 VAPP and cVDPV2 [7].
This switch from tOPV to bivalent OPV (bOPV) will significantly
reduce the burden of VAPP, but Sabin Like 2 that was circulating
https://doi.org/10.1016/j.jvacx.2020.100067
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prior to cessation could continue to circulate and lead to outbreaks
of cVDPV2, further the risk of type 2 disease persists due to the
sporadic emergence of type 2 circulating vaccine-derived polio-
virus (cVDPV2), containment breaches, and persistent shedding
from type 2-infected immunocompromised individuals in rare
events [8,9]. An OPV2 response will be required if such outbreaks
occur [10]. After April 2016, monovalent OPV2 (mOPV2) is only
intended to be used in response to cVDPV2 outbreaks, with bOPV
substituted for tOPV in routine immunization with the addition
of inactivated polio vaccine (IPV) [10].
Since IPV does not provide primary mucosal immunity, out-
breaks caused by type 2 poliovirus require the use of monovalent
type 2 oral polio vaccine (mOPV2) [11]. While mOPV2 is necessary
to stop an outbreak, there is a risk that live Sabin 2 virus in the vac-
cine will circulate and eventually cause additional outbreaks of
cVDPV2 [12,13]. This risk increases if outbreak response campaigns
are not of sufficient quality (coverage) or quantity. Under the
assumed high potency of mOPV2, current outbreak response
guidelines recommend two mOPV2 campaigns in target areas
[14,15]. However, there is a need to better understand the actual
impact of mOPV2 campaigns to inform outbreak response policy.
On the contrary IPV does not provide primary mucosal immunity,
it can boost mucosal immunity among those who have previously
received OPV [16,17]. IPV can also limit pharyngeal shedding,
which is believed to be a minor contributor to transmission [11].
However, IPV is more difficult to deliver than OPV, and high cover-
age is difficult to ensure. Currently, there is a global IPV shortage,
and understanding the benefit of IPV in outbreak response cam-
paigns is important to determine how it should be prioritized for
that purpose.
In this paper, we present results from a sequential serological
survey of children aged 6–11 months in Pakistan, conducted
between November 2016 and October 2017. Studying this age
cohort allowed us to assess the change in type 2 population immu-
nity after tOPV cessation by comparing those born before and after
cessation i.e. April 2016. In addition, supplementary immunization
activities (SIAs) containing type 2 vaccine were also carried out
during the surveys, allowing us to assess their impact by compar-
ing children sampled before and after these campaigns. Notably, an
outbreak of cVDPV2 was detected in Quetta district on 20 October
2016, which prompted a mOPV2 outbreak response between 2 Jan-
uary and 23 March 2017, consisting of a single round in all of
Balochistan province and two rounds in Quetta district, followed
by a single IPV campaign in Quetta block (Quetta, Pishin, and Killa
Abdullah districts). Additionally, multiple IPV campaigns were car-
ried out elsewhere in the country in response to WPV1 circulation.
By comparing children sampled before and after campaigns and
comparing to areas without campaigns, our survey provides a
unique assessment of the impact of mOPV2 and IPV on population
seroprotection against type 2 poliovirus.
2. Methods
2.1. Survey methodology
A sequential cross-sectional serological survey was conducted
by Aga Khan University (AKU) in partnership with the polio
national and provincial emergency operations centers, with the
primary goal of informing and assessing strategies for stopping
poliovirus transmission. The survey was conducted in two phases
in each of 12 geographic strata (3 in Karachi, 3 in Quetta block, 2
in Peshawar, 2 in Khyber Pakhtunkhwa (KP)/Federally Adminis-
tered Tribal Areas (FATA), and 2 in Northern Sindh). These areas
were chosen for having recent evidence of WPV1 circulation. We
also collected data from Rawalpindi and Lahore areas which served
as control in phase 1 and phase 2 of the survey respectively.
For each phase of the survey, sampling in each geographic stra-
tum consisted of 25 clusters. Clusters were chosen using probabil-
ity proportional to size (PPS) and the polio program’s lot quality
assurance sampling (LQAS) sampling frame. Once clusters were
identified, field teams conducted a household enumeration and
randomly selected 12 households with a child in the target age
group (6–11 months) for participation in the study. Refusal and
locked households were not replaced. Cluster and household ran-
dom selection were done separately using the same methodology
for each survey phase.
Following consent from the caregiver, basic demographic infor-
mation, vaccination history, and socio-economic status data were
obtained for all children included in the survey, along with 2 ml
of venous blood that was drawn by trained phlebotomists. Ethical
approval was obtained from the ethical review committees of the
AKU.
2.2. Laboratory methodology
After clotting and centrifugation, sera were separated, trans-
ferred into labeled sterile cryovials and immediately stored in a
cold box with ice packs and transported to the nearest laboratory
collection point of AKU for further transportation to the AKU Nutri-
tion Research Laboratory in Karachi. In the laboratory, two aliquots
were prepared, one for backup and one for transport to the Centers
of Disease Control at Atlanta, USA for analysis by neutralization
assay [18]. In our survey the seropositivity was defined as titer of
poliovirus neutralizing antibody 1:8 [19].
2.3. Statistical methodology
The primary outcome was type 2 seropositivity. Overall
seropositivity was summarized separately by geographic strata,
survey phase and birth cohort. Survey data were augmented with
data on the number of supplementary immunization activities
(SIAs) for which each child would have been eligible. IPV SIAs tar-
geted children 4–23 months of age, while bOPV SIAs targeted all
children under 5 years of age. Children were excluded from analy-
ses of IPV SIA impact if they were present during an IPV SIA but
under 4 months old. To assess protection offered by routine immu-
nization only, immunity was assessed among children born after
tOPV cessation and who were not eligible for SIAs containing type
2 vaccine.
To estimate SIA impact, we summarized immunity by area and
SIA eligibility. SIAs that were conducted within 14 days of the
blood draw were also excluded, since an immune response would
not be expected without prior immunity. Where possible, we esti-
mated intention to treat (ITT) seroconversion of the SIA as
1 ð1 xpostÞ=ð1 xpreÞ where xpre and xpost are the seroprevalence
among children in an area before and after an intervention, who
were otherwise comparable in terms of other opportunities for
immunization. This was estimated by log-linked binomial regres-
sion. This model is a straightforward binomial generalised linear
model (GLM) and in addition to its use in the relative risk regres-
sion it is commonly used in the analysis of serial survey data where
age and time specific prevalence may be used to estimate age and
time specific incidence.
All analyses accounted for survey design. For simplicity of expo-
sition, we combined the three geographic strata in Karachi into a
single unit and the two geographic strata in Peshawar into a single
unit. When analyses included children from multiple strata or sur-
vey phases, each stratum was given the same weight, despite vary-
ing population sizes. This provided inference on immunity that is
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‘typical’ across areas, rather than population averages that would
be overly influenced by high population areas like Karachi. All
analyses were conducted using R software [20,21].
3. Results
3.1. Sample population
Table 1a shows demographic characteristics for each study area.
There were 7940 children from 626 primary sampling units. Data
and sample collection was started in November 2016 and ended
in September 2017. Data collection for a single phase in a single
geographic area lasted a median of 37 days (range 8–151 days).
Wealth quintile wise the survey areas were pretty similar as the
distribution of the population in the lowest wealth quintile was
found to be about 20% in all survey areas, however the illiteracy
rate of the respondents varied from 19% in Rawalpindi to 100% in
Killa Abdullah. The percentage of male children ranged from 46%
(Larkana) to 63% (Khyber). Immunization cards were available
from > 50% of the caregivers in all target locations except Killa
Abdullah, Larkana and Sukkur districts. Similarly, routine immu-
nization with 3 doses of OPV (OPV3) was lowest (34%) in Killa
Abdullah and highest (96%) in Lahore.
Table 1b shows the survey timing, timing of birth and eligibility
of IPV and mOPV SIA in each study area. During the survey we
identified children who were born before the switch, the data
showed that 51% children in Karachi, 40% in Quetta, 52% in Pishin,
62% in Peshawar, 48% in Larkana, 53% in Sukkur and 27% in Rawal-
pindi were born before the switch. We also found that survey areas
in Quetta, Killa Abdullah and Pishin were largely eligible for
mOPV2 SIA.
3.2. Overall seroprevalence
Immunity to serotypes 1 and 3 were > 90% for both phases and
across geographic strata, with the exceptions found in Pishin and
Killa Abdullah (Fig. 1). In contrast, type 2 seroprevalence was gen-
erally lower and more variable, ranging from 42% in Karachi in July
2017 to 89% in Pishin in May 2017. The large variation in type 2
immunity was due to a combination of the change from three
doses of tOPV to one dose of IPV in routine vaccination following
the tOPV cessation in 2016, variation in routine immunization cov-
erage across geographic strata, and differing opportunities to
Table 1a
Basic demographic characteristics for each study area.
Area Survey
Phase












Karachi 1 1003 75 21.5 38.8 52 73 73 79
2 971 75 21.6 33.7 53 84 68 74
Quetta 1 311 25 20.3 83.9 50 66 95 63
2 317 25 20.1 91.5 51 50 54 61
Killa Abdullah 1 312 26 20.2 98.7 50 34 55 26
2 326 25 20.2 100.0 52 40 34 40
Pishin 1 309 24 20.1 89.6 47 56 92 60
2 310 25 20.0 96.5 50 50 45 50
Peshawar 1 627 50 20.4 80.9 53 85 77 83
2 651 50 20.1 82.6 49 91 84 89
Khyber 1 301 25 20.2 95.4 63 73 73 63
Mardan & Swabi 1 314 25 20.1 63.0 56 86 90 94
2 309 25 20.1 68.0 51 57 89 86
Larkana 1 341 25 20.2 88.6 46 43 58 66
2 313 25 20.1 80.3 48 54 90 87
Sukkur 1 300 25 20.0 75.0 51 45 44 62
2 298 25 20.1 94.3 54 34 36 56
Rawalpindi
(Control)
1 327 26 20.1 19.2 52 93 95 98
Lahore (Control) 2 299 25 20.1 26.0 54 90 96 97
Table 1b
Survey timing, timing of birth, IPV SIA and mOPV eligibility for each study area.
Area Survey Phase Blood Drawn Birth Cohorts Born before switch (%) IPV SIA Eligibility (%) mOPV2 SIA Eligibility (%)
Karachi 1 Nov-16 Mar-17 Dec-15 Sep-16 51 35 0
2 Apr-17 Sep-17 May-16 Mar-17 0 48 0
Quetta 1 Jan-17 Feb-17 Feb-16 Aug-16 40 0 98
2 Jul-17 Jul-17 Aug-16 Jan-17 4 81 100
Killa Abdullah 1 Mar-17 Mar-17 Apr-16 Sep-16 0 0 100
2 Aug-17 Aug-17 Sep-16 Feb-17 0 72 95
Pishin 1 Dec-16 Jan-17 Jan-16 Jul-16 52 0 1
2 May-17 Jul-17 Jun-16 Jan-17 0 94 100
Peshawar 1 Dec-16 Feb-17 Dec-15 Aug-16 62 8 0%
2 Apr-17 Jul-17 Apr-16 Jan-17 0 70 0%
Khyber 1 Sep-17 Sep-17 Sep-16 Mar-17 0 17 0%
Mardan & Swabi 1 May-17 May-17 May-16 Nov-16 0 76 0%
2 Oct-17 Oct-17 Oct-16 Apr-17 0 0 0%
Larkana 1 Jan-17 Feb-17 Jan-16 Aug-16 48 0 0%
2 Aug-17 Aug-17 Aug-16 Feb-17 0 32 0%
Sukkur 1 Dec-16 Jan-17 Dec-15 Jul-16 53 0 0%
2 Apr-17 May-17 May-16 Nov-16 0 75 0%
Rawalpindi (Control) 1 Mar-17 Mar-17 Mar-16 Sep-16 27 0 0%
Lahore (Control) 2 May-17 Jul-17 Jun-16 Dec-16 0 0 0%
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receive supplementary type 2-containing vaccine across geo-
graphic strata and birth cohorts.
The overall type 2 seroprevalence declined in successive birth
cohorts relative to types 1 and 3 (Fig. 2). Those born in December
2015 were eligible for tOPV in routine immunization in addition
to tOPV SIAs conducted immediately prior to the vaccine switch,
resulting in about 84% type 2 seroprevalence. In contrast, only
about half of those born in 2017 were seropositive for type 2. For
all birth cohorts, seropositivity for types 1 and 3 was consistently
higher.
3.3. Effectiveness of IPV through routine immunization
To understand the protection offered through routine immu-
nization, seroprevalence was estimated among those who were
born after tOPV cessation and ineligible for mOPV2 or IPV SIAs.
Among these 1534 children, 50% were seropositive for type 2, rang-
ing from 28% in Pishin to 80% in Rawalpindi (Fig. 3).
3.4. Effectiveness of supplementary mOPV2 campaigns
The cVDPV2 outbreak response campaigns in Balochistan were
interspersed between serosurvey rounds, allowing evaluation of
the effect of those campaigns on population immunity. The impact
was seen most clearly in Pishin district, where the first round of the
serosurvey included many children who were born after tOPV ces-
sation and sampled before the outbreak response campaigns.
Among children whose only opportunity for type 2 immunization
was through routine immunization with IPV, type 2 seroprevalence
was 28% (Fig. 4 and Table 2 Figure Supplementary figure 1 and
Fig. 1. Seroprevalence for each survey area. Points represent estimates of seroprevalence, and lines indicate 95% confidence intervals. Dates on the x-axis indicate the median
month of the blood draw for children in the survey round.
Fig. 2. Seroprevalence by birth cohort. Points represent seroprevalence estimates, and lines indicate 95% confidence intervals. Dates on the x-axis indicate birth month in
year-month format.
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Supplementary figure 2). Following the first survey round in Pishin,
an mOPV2 SIA was carried out from 11 to 15 February 2017 in
Pishin, Killa Abdullah and Quetta, followed by an IPV SIA from 17
to 23 April 2017 targeting the same districts. For the second survey
round in Pishin district, carried out between May and July 2017,
type 2 seroprevalence was 89% among those eligible for both SIAs,
resulting in an ITT seroconversion of 83% for the combined
mOPV2 + IPV SIAs (95% CI: 78%88%).Fig. 5.
In neighboring Killa Abdullah district, the first round of the sur-
vey took place after the February mOPV2 SIA, but before the April
IPV SIA. Type 2 seroprevalence was 62% among children eligible for
the mOPV2 SIA (Fig. 4 and Table 2). For the second round in this
district, conducted in August 2017, seroprevalence among those
eligible for mOPV2 SIA and the additional IPV SIA was 64%. This
resulted in an ITT seroconversion of 5% for the IPV SIA conducted
after the mOPV2 SIA (95% CI: –23%  27%).
In Quetta district, the first round of the serosurvey was con-
ducted after a mOPV2 SIA was carried out from 2 to 6 January
2017. Blood was drawn largely during the subsequent mOPV2
SIA, too early for a serological response to be expected. Among
these children, seroprevalence was 72% (Fig. 4 and Table 2). The
second round of the survey in this district consisted of children
who were eligible for two mOPV2 SIAs and a single IPV SIA, as well
as a younger birth cohort that was born after January 2017, and
only eligible for the second mOPV2 SIA and the subsequent IPV
SIA. Type 2 seroprevalence was 71% for the younger
mOPV2 + IPV group and 83% for the 2  mOPV2 + 1  IPV group.
While power was limited to estimate an effect of the IPV campaign
(ITT seroconversion estimate 3%, 95% CI: 73–39%), this suggests
an ITT seroconversion of 39% (95% CI: 8–59%) for the combined
mOPV2 and IPV SIAs.
3.5. Effectiveness of supplementary IPV campaigns
Outside of Balochistan, IPV campaigns were carried out in
response to WPV1 outbreaks. The timing of the serological surveys
gave an opportunity to assess their impact. In Karachi, the first
round of serosurvey targeted children who were born after tOPV
Fig. 3. Type 2 seroprevalence through routine immunization, by study area. The heights of the bars represent seroprevalence while lines represent 95% confidence intervals.
Fig. 4. Seroprevalence among areas targeted with mOPV2. Bar height corresponds to seroprevalence, while lines show 95% confidence intervals.
A. Voorman et al. / Vaccine: X 5 (2020) 100067 5
cessation and ineligible for IPV SIAs. Among this group, type 2
seropositivity was 37%, compared to 57% among those eligible
for the IPV SIA, resulting in an ITT seroconversion of 31% (95% CI:
18–41%). A comparable trend was seen in Peshawar (43% serocon-
version, 95% CI: 29–54%) with an increase from 44% to 68%.
Larkana and Sukkur had similar timings of the SIAs and survey
rounds, but different trends in immunity among those eligible and
not for IPV SIAs. In Larkana, the impact of the IPV SIA was not sta-
tistically significant (ITT seroconversion of 22%, 95% CI: 9–45%),
while in Sukkur the SIAs improved immunity from 39% among
those with routine immunization in the first survey round, to
87% among those in the subsequent survey round and who were
eligible for an IPV SIA, compatible with an ITT seroconversion of
78% (95% CI: 68–85%).
In Khyber Pakhtunkhwa province, there was no reference group
that had blood sampled before the IPV SIA. In both Mardan and
Swabi districts, and in Khyber Agency, relatively high seropreva-
lence (approximately 80%) was seen among those eligible for an
IPV SIA.
4. Discussion
Following tOPV cessation, a decline in protection against dis-
ease due to poliovirus type 2 was anticipated. We estimate that
50% of children in post-cessation birth cohorts in Pakistan are
not protected against type 2 poliovirus, and as many as 72% of chil-
dren in areas with low routine immunization coverage. As these
new cohorts accumulate, it is likely that in the coming years the
protection against type 2 will further decline. This supports the
recommended two-dose IPV schedule, as well as efforts to improve
routine immunization in Pakistan [22]. This declining immunity
also highlights the increasing priority that should be given to ongo-
ing and future type 2 outbreaks.
Table 2
Effectiveness of IPV and mOPV2 campaigns on type 2 seroprevalence.
Reference Group Comparison Group
Area Intervention Vaccines Seroprevalence (%)
(95% CI)












Karachi IPV SIAs Routine
only
37 (31, 44) IPV SIA 57 (51, 62) 31 (18, 41)
Peshawar Routine
only
44 (36, 53) IPV SIA 68 (63, 73) 43 (29, 54)
Sukkur Routine
only
39 (31, 47) IPV SIA 87 (82, 92) 78 (68, 85)
Larkana Routine
only
50 (38, 62) IPV SIA 61 (52, 70) 22 (-9, 45)





63 (51, 76) IPV SIA 77 (70, 84) 38 (3, 61)









62 (55, 69) IPV SIA 64 (57, 70) 5 (–23, 27)
Quetta mOPV2
SIA
72 (65, 79) mOPV2 + IPV SIA 83 (78, 88) 39 (8, 59)
Fig. 5. Type 2 immunity by IPV SIA eligibility. Bar height corresponds to seroprevalence, while lines show 95% confidence intervals.
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The timing of our study allowed for measurement of the impact
of supplementary immunization activities using mOPV2 and IPV.
We observed a strong response for the combined impact of mOPV2
and IPV SIAs in Pishin district, consistent with 84% ITT seroconver-
sion, and resulting in 89% seropositivity among 6–11 months old
children who were eligible for both SIAs. However, in neighboring
Killa Abdullah district seroprevalence was only 64% among chil-
dren eligible for the same mOPV2 and IPV SIAs, and 62% among
those eligible for the mOPV2 SIA only. In Quetta district, an mOPV2
SIA alone resulted in 72% seroprevalence, while an additional
mOPV2 SIA and IPV SIA improved immunity to 83%. This supports
the findings in Voorman et al. 2017, who found that the first SIAs a
cohort experience are likely the most beneficial, while subsequent
SIAs have less impact [23]. As with that study, a likely explanation
in the current study is coverage, where children who are not
immunized in one SIA are highly likely to remain unimmunized
through subsequent SIAs. However, when comparing with type 1
and type 3 immunity, which benefit frommany more SIAs, we note
that high immunity was eventually achieved in the same
population.
Though the cVDPV2 outbreak in Balochistan has apparently
been stopped, this study cannot assess what immunity level is an
appropriate target for outbreak response. Our study involved chil-
dren 6–11 months old, chosen as the most vulnerable age group.
However, the contribution of older age groups with higher immu-
nity and prior tOPV exposure was likely relevant to the apparent
termination of the cVDPV2 outbreak in Quetta.
Our results show that IPV SIAs can have a substantial effect on
type 2 seroprotection in settings of low immunity. The impact of
IPV campaigns on transmission could not be determined, since
the study did not assess viral shedding or mucosal immunity.
The study is limited by its observational nature. Cohorts and sam-
ple collection were not designed to evaluate routine immunization
and SIA impact; as a result, while age is important for vaccine effi-
cacy, the age at which an SIA occurred is not the same between com-
parison groups. Likewise, sources of immunity could not be cleanly
distinguished, and there remain some survey areas for which there
is no simple explanation for the observed data. Seroprevalence in
Rawalpindi (80%) is greater than one would expect from a single
dose of IPV that 85% of the children reported. Further, it contrasts
with much lower protection in Lahore, where 70% of children
reported three doses of IPV, likely from private clinics.
5. Conclusions
Type 2 immunity has declined among cohorts born after tOPV
cessation in Pakistan and, thus, overall population protection
against type 2 poliovirus will decline without both improvements
in routine immunization and introduction of two or more doses of
IPV. While risk of type 2 polio outbreaks is likely decreasing in Pak-
istan, the ability of an outbreak to spread rapidly is increasing.
Supplementary immunization campaigns with mOPV2 and/or
IPV resulted in substantial improvements in seroprotection in
some survey areas, but the effect was not uniform. The vaccine
used in an SIA, whether mOPV2, IPV, or both, is not a guarantee
of high population immunity to type 2 poliovirus. Further, the
impact of subsequent SIAs beyond the first was lower in general,
suggesting that children missed in one SIA are more likely to
remain missed in subsequent SIAs.
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